MIC-based dose adjustment: Facts and fables

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 3, 2018, Pages 564-568

  Mouton, Johan W ^a   Muller, Anouk E ^a,b   Canton, Rafael ^c   Giske, Christian G ^d   Kahlmeter, Gunnar ^e   Turnidge, John ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL GROWTH; BIOLOGICAL VARIATION; CLINICAL LABORATORY; CLINICAL PRACTICE; DRUG MONITORING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; SPECIES IDENTIFICATION; STAPHYLOCOCCUS AUREUS; BACTERIUM; DOSE RESPONSE; DRUG EFFECT; MICROBIAL SENSITIVITY TEST; PROCEDURES; REPRODUCIBILITY; STANDARDS;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOLOGICAL VARIATION, POPULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS;

EID: 85043324373     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx427     Document Type: Article

References (24)

1. Economou CJP, Wong G, McWhinney B et al. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2017; 49: 589-94.
2. Charmillon A, Novy E, Agrinier N et al. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect 2016; 22: 625-31.
3. Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69: 1416-23.
4. Jager NG, van Hest RM, Lipman J et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol 2016; 9: 961-79.
5. International Organization for Standardization (ISO). ISO 20776-1. Clinical Laboratory Testing and In Vitro Diagnostic Test Systems-Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Testing Devices-Part 1. ISO, 2006.
6. Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10.
7. Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Investig 1996; 11: 229-39.
8. Mouton JW, Vinks AA. Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. Clin Pharmacokinet 2005; 44: 767-8.
9. Voss A, Mouton JW, van Elzakker EPM et al. Linezolid susceptibility of glycopeptide-intermediately susceptible Staphylococcus aureus (GISA)-the Dutch experience. In: Abstracts of the Thirteenth European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 2003. Abstract P1309. ESCMID, Basel, Switzerland.
10. International Organization for Standardization (ISO). ISO 20776-2. Clinical Laboratory Testing and In Vitro Diagnostic Test Systems-Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Testing Devices-Part 2. ISO, 2008.
11. Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. JAntimicrobChemother 2003; 52: 145-8.
12. Kahlmeter G. The 2014 Garrod Lecture: EUCAST-are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427-39.
13. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
14. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
15. Abdul-Aziz MH, Lipman J, Mouton JW et al. Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-53.
16. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
17. Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
18. Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the newtransmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J ClinMicrobiol 2009; 47: 2751-8.
19. Kohner PC, Robberts FJ, Cockerill FR 3rd et al. Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J ClinMicrobiol 2009; 47: 2419-25.
20. Skov R, Matuschek E, Sjölund-Karlsson M et al. Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica. JClinMicrobiol 2015; 53: 3411-7.
21. EUCAST. https://mic.eucast.org/Eucast2/.
22. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
23. Huttner A, Harbarth S, Hope WW et al. Therapeutic drug monitoring of the β-lactamantibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015; 70: 3178-83.
24. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.